Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6512770 | 0.94 | AURKA (0.50) | AURKAKDRAURKBMAPTMEN1 | |
| SCHEMBL6522416 | 0.90 | MAPT (0.49) | AURKAKDRAURKBMAPTMEN1 | |
| SCHEMBL6517711 | 0.83 | CHEK1 (0.55) | AURKAKDRAURKBMAPTCHEK1 | |
| SCHEMBL6508702 | 0.82 | CHEK1 (0.56) | AURKAKDRAURKBMAPTCHEK1 | |
| SCHEMBL6523086 | 0.81 | AURKA (0.57) | AURKAKDRAURKBMEN1KMT2A | |
| SCHEMBL6508848 | 0.80 | AURKA (0.54) | AURKAKDRAURKBKMT2ACHEK1 | |
| SCHEMBL6518336 | 0.80 | TP53 (0.54) | AURKAKDRAURKBMAPTMEN1 | |
| SCHEMBL6514590 | 0.79 | AURKA (0.46) | AURKAKDRAURKBMAPTMEN1 | |
| SCHEMBL6510076 | 0.79 | AURKA (0.57) | AURKAKDRAURKBCHEK1TP53 | |
| SCHEMBL6518613 | 0.79 | AURKA (0.52) | AURKAKDRAURKBMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | AURKA 78/4885KDR 1094/4885AURKB 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.